Blood Screening Market Size, Share, Growth Analysis, By Product & Service (Reagents & Kits [NAT Reagents & Kits, ELISA Reagents & Kits, Other Reagents & Kits], Instruments [Rental Purchase), By Technology (Nucleic Acid Test (NAT) [Transcription-mediated Amplification (TMA), Real-time Polymerase Chain Reaction (RT-PCR)], Serology/Immunoassay [Chemiluminescent Immunoassays (CLIA), Fluorescent Immunoassays (FIA)), By End User (Hospitals & Clinics, Diagnostic centers, Blood Banks), By Region - Industry Forecast 2025-2032

Blood Screening Market size was valued at USD 3.3 Billion in 2023 and is poised to grow from USD 3.58 Billion in 2024 to USD 6.87 Billion by 2032, growing at a CAGR of 8.50% during the forecast period (2025-2032).

The growing demand for safe blood worldwide along with technological advancements in screening technologies is molding this industry's future. The overall healthcare ecosystem all over the globe is heavily reliant on the screening technologies sector by incorporating market trends, challenges, and prospects. Primarily, the blood screening market is being driven forward by the increased rate of blood donation globally. The more people donate blood, the more meticulous screening procedures become a necessity in ensuring the blood is safe to be used. Due to this surge in contributions, screening methods are being adopted in blood banks and medical facilities to properly manage it. This is particularly true in countries with long-standing government support for blood collection initiatives, as increased donations are partly supported by superior facility infrastructure and public sensitization. Recent advanced blood tests for infections are very much in demand owing to the rising volumes of donations as they are required to ensure that transmitted blood does not harbor infectious organisms and thus ensures receiver safety.

Public health remains not entirely unconcerned about the spread of infectious diseases, especially in regions with a lack of good access to high-tech healthcare delivery. Its necessity for stricter blood screening techniques has been highlighted by the increasing prevalence of diseases such as HIV, hepatitis B and C, and the Zika virus. Since blood transfusion is one of the many routes through which these infectious diseases are transmitted, governments and institutions that take care of patients are becoming more conscious about adopting more efficient blood screening technology. Consequently, chemiluminescence immunoassays (CLIA), nucleic acid amplification tests (NAT), and other ultra-sensitive techniques have become the common tools used in most blood screening centers.

US Blood Screening Market is poised to grow at a sustainable CAGR for the next forecast year.